Literature DB >> 23879825

Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study.

Maria Pagoldh1, Elin Hultgren, Per Arnell, Anders Eriksson.   

Abstract

BACKGROUND AND AIMS: Complementary therapy options are needed in the treatment of active ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) has been shown to have positive effects in experimental models of colitis and perianal Crohn's disease.
METHODS: In the present prospective randomized open-label study, HBOT in addition to conventional medical treatment was compared with conventional treatment alone. The primary objective in this study was improved clinical outcome evaluated by Mayo score, laboratory tests and fecal weight. The secondary objectives were improvement in health-related quality of life, avoidance of colectomy and evaluation of HBOT safety.
RESULTS: The authors found no statistically significant differences between the treatment groups in any of the assessed variables.
CONCLUSION: The study results do not support the use of HBOT as a treatment option in a severe attack of UC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23879825     DOI: 10.3109/00365521.2013.819443

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  3 in total

1.  Hyperbaric Oxygen Therapy in Systemic Inflammatory Response Syndrome.

Authors:  Débora Gouveia; Mariana Chichorro; Ana Cardoso; Carla Carvalho; Cátia Silva; Tiago Coelho; Isabel Dias; António Ferreira; Ângela Martins
Journal:  Vet Sci       Date:  2022-01-18

Review 2.  The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review.

Authors:  Xin Wu; Tian-Yu Liang; Zhong Wang; Gang Chen
Journal:  Med Gas Res       Date:  2021 Apr-Jun

3.  Systematic review with meta-analysis: effectiveness of hyperbaric oxygenation therapy for ulcerative colitis.

Authors:  Pingrun Chen; Yina Li; Xian Zhang; Yan Zhang
Journal:  Therap Adv Gastroenterol       Date:  2021-07-17       Impact factor: 4.409

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.